|
|
||||||||
From the Departments of Neurology (Mellen Center) (Dr. Rudick), Biomedical Engineering (Dr. Fisher), and Biostatistics and Epidemiology (J.-C. Lee), Cleveland Clinic Foundation, Cleveland, OH; the Department of RadiologyMRI (Dr. Simon), University of Colorado Health Sciences Center, Denver, CO; and the Department of Neurology (Dr. Jacobs), Buffalo General Hospital, Buffalo, NY.
Address correspondence and reprint requests to Dr. Rudick, Area U100, Mellen Center, Cleveland Clinic Foundation, Cleveland, OH 44195.
BACKGROUND: Episodic inflammation in the CNS during the early stages of MS results in progressive disability years later, presumably due to myelin and axonal injury. MRI demonstrates ongoing disease activity during the early disease stage, even in some patients who are stable clinically. The optimal MRI measure for the destructive pathologic process is uncertain, however.
METHODS: In this post-hoc study, MRI scans were analyzed from patients with relapsing MS participating in a placebo-controlled trial of interferon ß-1a. The brain parenchymal fraction, defined as the ratio of brain parenchymal volume to the total volume within the brain surface contour, was used to measure whole brain atrophy. The relationship between disease features and brain atrophy and effect of interferon ß-1a were determined.
RESULTS: MS patients had significant brain atrophy that worsened during each of 2 years of observation. In many patients, brain atrophy worsened without clinical disease activity. Baseline clinical and MRI abnormalities were not strongly related to the rate of brain atrophy during the subsequent 2 years. Treatment with interferon ß-1a resulted in a reduction in brain atrophy progression during the second year of the clinical trial.
CONCLUSIONS: Patients with relapsing-remitting MS have measurable amounts of whole brain atrophy that worsens yearly, in most cases without clinical manifestations. The brain parenchymal fraction is a marker for destructive pathologic processes ongoing in relapsing MS patients, and appears useful in demonstrating treatment effects in controlled clinical trials.
Key words: MSMRIBrain atrophyInterferon beta.
This article has been cited by other articles:
![]() |
B Healy, P Valsasina, M Filippi, and R Bakshi Sample size requirements for treatment effects using gray matter, white matter and whole brain volume in relapsing-remitting multiple sclerosis J. Neurol. Neurosurg. Psychiatry, November 1, 2009; 80(11): 1218 - 1224. [Abstract] [Full Text] [PDF] |
||||
![]() |
E Havrdova, R Zivadinov, J Krasensky, M. Dwyer, I Novakova, O Dolezal, V Ticha, L Dusek, E Houzvickova, J. Cox, et al. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis Multiple Sclerosis, August 1, 2009; 15(8): 965 - 976. [Abstract] [PDF] |
||||
![]() |
L. Mehta, S. Schwid, D. Arnold, G. Cutter, S Aradhye, L. Balcer, P. Calabresi, J. Cohen, P. Cole, R Glanzman, et al. Proof of concept studies for tissue-protective agents in multiple sclerosis Multiple Sclerosis, May 1, 2009; 15(5): 542 - 546. [Abstract] [PDF] |
||||
![]() |
R. A. Rudick and E. Fisher Brain atrophy as an outcome measure for multiple sclerosis clinical trials: A "no-brainer"? Neurology, February 17, 2009; 72(7): 586 - 587. [Full Text] [PDF] |
||||
![]() |
D. R. Altmann, B. Jasperse, F. Barkhof, K. Beckmann, M. Filippi, L. D. Kappos, P. Molyneux, C. H. Polman, C. Pozzilli, A. J. Thompson, et al. Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis Neurology, February 17, 2009; 72(7): 595 - 601. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Cohen, P. B. Imrey, P. A. Calabresi, K. R. Edwards, T. Eickenhorst, W. L. Felton III, E. Fisher, R. J. Fox, A. D. Goodman, C. Hara-Cleaver, et al. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS Neurology, February 10, 2009; 72(6): 535 - 541. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Gauthier, A. M. Berger, Z. Liptak, Y. Duan, S. Egorova, G. J. Buckle, B. I. Glanz, S. J. Khoury, R. Bakshi, H. L. Weiner, et al. Rate of Brain Atrophy in Benign vs Early Multiple Sclerosis Arch Neurol, February 1, 2009; 66(2): 234 - 237. [Abstract] [Full Text] [PDF] |
||||
![]() |
G Tedeschi, D Dinacci, M Comerci, L Lavorgna, G Savettieri, A Quattrone, P Livrea, F Patti, V Brescia Morra, G Servillo, et al. Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study Multiple Sclerosis, February 1, 2009; 15(2): 204 - 211. [Abstract] [PDF] |
||||
![]() |
B Brochet, M. Deloire, M Bonnet, E Salort-Campana, J. Ouallet, K. Petry, and V Dousset Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study Multiple Sclerosis, November 1, 2008; 14(9): 1242 - 1249. [Abstract] [PDF] |
||||
![]() |
M. Mandel and R. A. Betensky Estimating time-to-event from longitudinal ordinal data using random-effects Markov models: application to multiple sclerosis progression Biostat., October 1, 2008; 9(4): 750 - 764. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Racke Editorial: Challenges in developing new multiple sclerosis therapies Therapeutic Advances in Neurological Disorders, September 1, 2008; 1(2): 63 - 65. [PDF] |
||||
![]() |
R. Fox, P Kivisakk, E Fisher, B Tucky, J. Lee, R. Rudick, and R. Ransohoff Multiple sclerosis: chemokine receptor expression on circulating lymphocytes in correlation with radiographic measures of tissue injury Multiple Sclerosis, September 1, 2008; 14(8): 1036 - 1043. [Abstract] [PDF] |
||||
![]() |
R. Zivadinov, A. T. Reder, M. Filippi, A. Minagar, O. Stuve, H. Lassmann, M. K. Racke, M. G. Dwyer, E. M. Frohman, and O. Khan Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis Neurology, July 8, 2008; 71(2): 136 - 144. [Abstract] [Full Text] [PDF] |
||||
![]() |
D Horakova, J L Cox, E Havrdova, S Hussein, O Dolezal, D Cookfair, M G Dwyer, Z Seidl, N Bergsland, M Vaneckova, et al. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study J. Neurol. Neurosurg. Psychiatry, April 1, 2008; 79(4): 407 - 414. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Cohen, P. Calabresi, S. Chakraborty, K. Edwards, T. Eickenhorst, W. Felton III, E. Fisher, R. Fox, A. Goodman, C. Hara-Cleaver, et al. Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data Multiple Sclerosis, April 1, 2008; 14(3): 370 - 382. [Abstract] [PDF] |
||||
![]() |
D.S. Reich, K.M. Zackowski, E.M. Gordon-Lipkin, S.A. Smith, B.A. Chodkowski, G.R. Cutter, and P.A. Calabresi Corticospinal Tract Abnormalities Are Associated with Weakness in Multiple Sclerosis AJNR Am. J. Neuroradiol., February 1, 2008; 29(2): 333 - 339. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Gordon-Lipkin, B. Chodkowski, D. S. Reich, S. A. Smith, M. Pulicken, L. J. Balcer, E. M. Frohman, G. Cutter, and P. A. Calabresi Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis Neurology, October 16, 2007; 69(16): 1603 - 1609. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Calabrese, N. De Stefano, M. Atzori, V. Bernardi, I. Mattisi, L. Barachino, A. Morra, L. Rinaldi, C. Romualdi, P. Perini, et al. Detection of Cortical Inflammatory Lesions by Double Inversion Recovery Magnetic Resonance Imaging in Patients With Multiple Sclerosis Arch Neurol, October 1, 2007; 64(10): 1416 - 1422. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P. Lisak Neurodegeneration in multiple sclerosis: Defining the problem Neurology, May 29, 2007; 68(22_suppl_3): S5 - S12. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Dutta and B. D. Trapp Pathogenesis of axonal and neuronal damage in multiple sclerosis Neurology, May 29, 2007; 68(22_suppl_3): S22 - S31. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Arnold Evidence for neuroprotection and remyelination using imaging techniques Neurology, May 29, 2007; 68(22_suppl_3): S83 - S90. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Zivadinov, L. Locatelli, D. Cookfair, B. Srinivasaraghavan, A. Bertolotto, M. Ukmar, A. Bratina, C. Maggiore, A. Bosco, A. Grop, et al. I nterferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy Multiple Sclerosis, May 1, 2007; 13(4): 490 - 501. [Abstract] [PDF] |
||||
![]() |
D. H. Miller, D. Soon, K. T. Fernando, D. G. MacManus, G. J. Barker, T. A. Yousry, E. Fisher, P. W. O'Connor, J. T. Phillips, C. H. Polman, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS Neurology, April 24, 2007; 68(17): 1390 - 1401. [Abstract] [Full Text] [PDF] |
||||
![]() |
D.M. Mezzapesa, A. Ceccarelli, F. Dicuonzo, A. Carella, M.F. De Caro, M. Lopez, V. Samarelli, P. Livrea, and I.L. Simone Whole-Brain and Regional Brain Atrophy in Amyotrophic Lateral Sclerosis AJNR Am. J. Neuroradiol., February 1, 2007; 28(2): 255 - 259. [Abstract] [Full Text] [PDF] |
||||
![]() |
B Audoin, D Ibarrola, I Malikova, E Soulier, S Confort-Gouny, M-V A. Duong, F Reuter, P Viout, A Ali-Cherif, P J Cozzone, et al. Onset and underpinnings of white matter atrophy at the very early stage of multiple sclerosis - a two-year longitudinal MRI/MRSI study of corpus callosum Multiple Sclerosis, January 1, 2007; 13(1): 41 - 51. [Abstract] [PDF] |
||||
![]() |
J H Simon Brain atrophy in multiple sclerosis: what we know and would like to know Multiple Sclerosis, November 1, 2006; 12(6): 679 - 687. [Abstract] [PDF] |
||||
![]() |
F. Bagnato, J.A. Butman, S. Gupta, M. Calabrese, L. Pezawas, J.M. Ohayon, F. Tovar-Moll, M. Riva, M.M. Cao, S.L. Talagala, et al. In Vivo Detection of Cortical Plaques by MR Imaging in Patients with Multiple Sclerosis AJNR Am. J. Neuroradiol., November 1, 2006; 27(10): 2161 - 2167. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Sepulcre, J. Sastre-Garriga, M. Cercignani, G. T. Ingle, D. H. Miller, and A. J. Thompson Regional Gray Matter Atrophy in Early Primary Progressive Multiple Sclerosis: A Voxel-Based Morphometry Study. Arch Neurol, August 1, 2006; 63(8): 1175 - 1180. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Chen, D. L. Collins, H. L. Atkins, M. S. Freedman, A. Galal, D. L. Arnold, and the Canadian MS BMT Study Group Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis Neurology, June 27, 2006; 66(12): 1935 - 1937. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. B. J. Morales, K. K. Loo, H.-b. Liu, C. Peterson, S. Tiwari-Woodruff, and R. R. Voskuhl Treatment with an estrogen receptor alpha ligand is neuroprotective in experimental autoimmune encephalomyelitis. J. Neurosci., June 21, 2006; 26(25): 6823 - 6833. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Frohman, E. Havrdova, F. Lublin, F. Barkhof, A. Achiron, M. K. Sharief, O. Stuve, M. K. Racke, L. Steinman, H. Weiner, et al. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol, April 1, 2006; 63(4): 614 - 619. [Full Text] [PDF] |
||||
![]() |
C. Confavreux and S. Vukusic Natural history of multiple sclerosis: a unifying concept Brain, March 1, 2006; 129(3): 606 - 616. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. D. Richert, T. Howard, J. A. Frank, R. Stone, J. Ostuni, J. Ohayon, C. Bash, and H. F. McFarland Relationship between inflammatory lesions and cerebral atrophy in multiple sclerosis Neurology, February 28, 2006; 66(4): 551 - 556. [Abstract] [Full Text] [PDF] |
||||
![]() |
D R Smith, B Weinstock-Guttman, J A Cohen, X Wei, C Gutmann, R Bakshi, M Olek, L Stone, S Greenberg, D Stuart, et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta Multiple Sclerosis, October 1, 2005; 11(5): 573 - 582. [Abstract] [PDF] |
||||
![]() |
H. Krapf, S. P. Morrissey, O. Zenker, T. Zwingers, R. Gonsette, H. -P. Hartung, and the MIMS Study Group Effect of mitoxantrone on MRI in progressive MS: Results of the MIMS trial Neurology, September 13, 2005; 65(5): 690 - 695. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Bermel, S. R. Puli, R. A. Rudick, B. Weinstock-Guttman, E. Fisher, F. E. Munschauer III, and R. Bakshi Prediction of Longitudinal Brain Atrophy in Multiple Sclerosis by Gray Matter Magnetic Resonance Imaging T2 Hypointensity Arch Neurol, September 1, 2005; 62(9): 1371 - 1376. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M Herndon, R. A Rudick, F. E Munschauer III, M. K Mass, A. M Salazar, M. E Coats, R. Labutta, J. R Richert, S. L Cohan, C. Genain, et al. Eight-year immunogenicity and safety of interferon beta-1a-Avonex(R)treatment in patients with multiple sclerosis Multiple Sclerosis, August 1, 2005; 11(4): 409 - 419. [Abstract] [PDF] |
||||
![]() |
I R Moldovan, R A Rudick, A C Cotleur, S E Born, J-C Lee, M T Karafa, and C M Pelfrey Longitudinal single-cell cytokine responses reveal recurrent autoimmune myelin reactivity in relapsing-remitting multiple sclerosis patients Multiple Sclerosis, June 1, 2005; 11(3): 251 - 260. [Abstract] [PDF] |
||||
![]() |
J. Sastre-Garriga, G. T. Ingle, D. T. Chard, M. Cercignani, L. Ramio-Torrenta, D. H. Miller, and A. J. Thompson Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study Brain, June 1, 2005; 128(6): 1454 - 1460. [Abstract] [Full Text] [PDF] |
||||
![]() |
M S A Deloire, E Salort, M Bonnet, Y Arimone, M Boudineau, H Amieva, B Barroso, J-C Ouallet, C Pachai, E Galliaud, et al. Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis J. Neurol. Neurosurg. Psychiatry, April 1, 2005; 76(4): 519 - 526. [Abstract] [Full Text] [PDF] |
||||
![]() |
J Versijpt, J C Debruyne, K J Van Laere, F De Vos, J Keppens, K Strijckmans, E Achten, G Slegers, R A Dierckx, J Korf, et al. Microglial imaging with positron emission tomography and atrophy measurements with magnetic resonance imaging in multiple sclerosis: a correlative study Multiple Sclerosis, April 1, 2005; 11(2): 127 - 134. [Abstract] [PDF] |
||||
![]() |
R. J Fox, E. Fisher, J. Tkach, J.-C. Lee, J. A Cohen, and R. A Rudick Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications Multiple Sclerosis, April 1, 2005; 11(2): 140 - 145. [Abstract] [PDF] |
||||
![]() |
K. Biernacki, J. P. Antel, M. Blain, S. Narayanan, D. L. Arnold, and A. Prat Interferon Beta Promotes Nerve Growth Factor Secretion Early in the Course of Multiple Sclerosis Arch Neurol, April 1, 2005; 62(4): 563 - 568. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tiberio, D. T. Chard, D. R. Altmann, G. Davies, C. M. Griffin, W. Rashid, J. Sastre-Garriga, A. J. Thompson, and D. H. Miller Gray and white matter volume changes in early RRMS: A 2-year longitudinal study Neurology, March 22, 2005; 64(6): 1001 - 1007. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hardmeier, S. Wagenpfeil, P. Freitag, E. Fisher, R. A. Rudick, M. Kooijmans, M. Clanet, E. W. Radue, L. Kappos, and for the European IFNss-1a in Relapsing MS Dose Com Rate of brain atrophy in relapsing MS decreases during treatment with IFN{beta}-1a Neurology, January 25, 2005; 64(2): 236 - 240. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Bakshi, G. J. Hutton, J. R. Miller, and E.-W. Radue The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis Neurology, December 14, 2004; 63(11_suppl_5): S3 - S11. [Abstract] [Full Text] |
||||
![]() |
W. H. Stuart, S. Cohan, J. R. Richert, and A. Achiron Selecting a disease-modifying agent as platform therapy in the long-term management of multiple sclerosis Neurology, December 14, 2004; 63(11_suppl_5): S19 - S27. [Abstract] [Full Text] |
||||
![]() |
S Ozakbas, B Ormeci, B B.K. Akdede, K Alptekin, and E Idiman Utilization of the auditory consonant trigram test to screen for cognitive impairment in patients with multiple sclerosis: comparison with the paced auditory serial addition test Multiple Sclerosis, December 1, 2004; 10(6): 686 - 689. [Abstract] [PDF] |
||||
![]() |
Y. C. Zang, S. M Skinner, R. R Robinson, S. Li, V. M Rivera, G. J Hutton, and J. Z Zhang Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis Multiple Sclerosis, October 1, 2004; 10(5): 499 - 506. [Abstract] [PDF] |
||||
![]() |
L. Locatelli, R. Zivadinov, A. Grop, and M. Zorzon Frontal parenchymal atrophy measures in multiple sclerosis Multiple Sclerosis, October 1, 2004; 10(5): 562 - 568. [Abstract] [PDF] |
||||
![]() |
F. M. Boneschi, M. Rovaris, G. Comi, and M. Filippi The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials Multiple Sclerosis, August 1, 2004; 10(4): 341 - 347. [Abstract] [PDF] |
||||
![]() |
X. Wei, C. R. Guttmann, S. K Warfield, M. Eliasziw, and J R. Mitchell Has your patient's multiple sclerosis lesion burden or brain atrophy actually changed? Multiple Sclerosis, August 1, 2004; 10(4): 402 - 406. [Abstract] [PDF] |
||||
![]() |
M. P. Amato, M. L. Bartolozzi, V. Zipoli, E. Portaccio, M. Mortilla, L. Guidi, G. Siracusa, S. Sorbi, A. Federico, and N. De Stefano Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment Neurology, July 13, 2004; 63(1): 89 - 93. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Sharma, M. P. Sanfilipo, R. H. B. Benedict, B. Weinstock-Guttman, F. E. Munschauer III, and R. Bakshi Whole-Brain Atrophy in Multiple Sclerosis Measured by Automated versus Semiautomated MR Imaging Segmentation AJNR Am. J. Neuroradiol., June 1, 2004; 25(6): 985 - 996. [Abstract] [Full Text] [PDF] |
||||
![]() |
F G Maggs and J Palace The pathogenesis of multiple sclerosis: is it really a primary inflammatory process? Multiple Sclerosis, June 1, 2004; 10(3): 326 - 329. [Abstract] [PDF] |
||||
![]() |
R. T. Staff, A. D. Murray, I. J. Deary, and L. J. Whalley What provides cerebral reserve? Brain, May 1, 2004; 127(5): 1191 - 1199. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. De Stefano, M. L. Bartolozzi, B. Nacmias, V. Zipoli, M. Mortilla, L. Guidi, G. Siracusa, S. Sorbi, A. Federico, and M. P. Amato Influence of Apolipoprotein E {epsilon}4 Genotype on Brain Tissue Integrity in Relapsing-Remitting Multiple Sclerosis Arch Neurol, April 1, 2004; 61(4): 536 - 540. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Frank, N. Richert, C. Bash, L. Stone, P. A. Calabresi, B. Lewis, R. Stone, T. Howard, and H. F. McFarland Interferon-{beta}-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients Neurology, March 9, 2004; 62(5): 719 - 725. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Malmestrom, S. Haghighi, L. Rosengren, O. Andersen, and J. Lycke Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS Neurology, December 23, 2003; 61(12): 1720 - 1725. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hardmeier, S. Wagenpfeil, P. Freitag, E. Fisher, R. A. Rudick, M. Kooijmans-Coutinho, M. Clanet, E. W. Radue, and L. Kappos Atrophy Is Detectable Within a 3-Month Period in Untreated Patients With Active Relapsing Remitting Multiple Sclerosis Arch Neurol, December 1, 2003; 60(12): 1736 - 1739. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. M. Parry, R. B. Scott, J. Palace, S. Smith, and P. M. Matthews Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine Brain, December 1, 2003; 126(12): 2750 - 2760. [Abstract] [Full Text] [PDF] |
||||
![]() |
X Lin, C R Tench, B Turner, L D Blumhardt, and C S Constantinescu Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon {beta}-1a (Rebif) treatment trial J. Neurol. Neurosurg. Psychiatry, August 1, 2003; 74(8): 1090 - 1094. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sailer, B. Fischl, D. Salat, C. Tempelmann, M. A. Schonfeld, E. Busa, N. Bodammer, H.-J. Heinze, and A. Dale Focal thinning of the cerebral cortex in multiple sclerosis Brain, August 1, 2003; 126(8): 1734 - 1744. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Zarei, S Chandran, A Compston, and J Hodges Cognitive presentation of multiple sclerosis: evidence for a cortical variant J. Neurol. Neurosurg. Psychiatry, July 1, 2003; 74(7): 872 - 877. [Abstract] [Full Text] [PDF] |
||||
![]() |
D Pelletier, S J Nelson, J Oh, J P Antel, M Kita, S S Zamvil, and D E Goodkin MRI lesion volume heterogeneity in primary progressive MS in relation with axonal damage and brain atrophy J. Neurol. Neurosurg. Psychiatry, July 1, 2003; 74(7): 950 - 952. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Christodoulou, L. B. Krupp, Z. Liang, W. Huang, P. Melville, C. Roque, W. F. Scherl, T. Morgan, W. S. MacAllister, L. Li, et al. Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients Neurology, June 10, 2003; 60(11): 1793 - 1798. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Dichgans, B. Putz, D. Boos, and D. P. Auer Role of Subvoxel Free Fluid on Diffusion Parameters in Brain Tissue with Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy and Its Correlation with Physical Disability: Histogram Analysis of Standard and Fluid-Attenuated MR Diffusion AJNR Am. J. Neuroradiol., June 1, 2003; 24(6): 1083 - 1089. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. V. Toyka and R. Gold The pathogenesis of CIDP: Rationale for treatment with immunomodulatory agents Neurology, April 22, 2003; 60(90083): S2 - 7. [Abstract] [Full Text] |
||||
![]() |
J.-M. Vallat, A.F. Hahn, J.-M. Leger, D.P. Cros, L. Magy, F. Tabaraud, P. Bouche, and P.-M. Preux Interferon beta-1a as an investigational treatment for CIDP Neurology, April 22, 2003; 60(90083): S23 - 28. [Abstract] [Full Text] |
||||
![]() |
N. De Stefano, P. M. Matthews, M. Filippi, F. Agosta, M. De Luca, M. L. Bartolozzi, L. Guidi, A. Ghezzi, E. Montanari, A. Cifelli, et al. Evidence of early cortical atrophy in MS: Relevance to white matter changes and disability Neurology, April 8, 2003; 60(7): 1157 - 1162. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Rudick Mechanisms of disability progression in primary progressive multiple sclerosis: are they different from secondary progressive multiple sclerosis? Multiple Sclerosis, April 1, 2003; 9(2): 210 - 212. [PDF] |
||||
![]() |
C. Confavreux, S. Vukusic, and P. Adeleine Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process Brain, April 1, 2003; 126(4): 770 - 782. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M Miller, R. A Rudick, M. Baier, G. Cutter, D. S Doughtery, B. Weinstock-Guttman, M. K Mass, E. Fisher, and N. Simonian Factors that predict Health-Related Q uality of Life in patients with relapsing -remitting multiple sclerosis Multiple Sclerosis, February 1, 2003; 9(1): 1 - 5. [Abstract] [PDF] |
||||
![]() |
B. Turner, X. Lin, G. Calmon, N. Roberts, and L. D Blumhardt C erebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years Multiple Sclerosis, February 1, 2003; 9(1): 21 - 27. [Abstract] [PDF] |
||||
![]() |
M. Filippi, M. Bozzali, M. Rovaris, O. Gonen, C. Kesavadas, A. Ghezzi, V. Martinelli, R. I. Grossman, G. Scotti, G. Comi, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis Brain, February 1, 2003; 126(2): 433 - 437. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Caon, M. Zvartau-Hind, W. Ching, R.P. Lisak, A.C. Tselis, and O.A. Khan Intercaudate nucleus ratio as a linear measure of brain atrophy in multiple sclerosis Neurology, January 28, 2003; 60(2): 323 - 325. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Burks, B. G. Arnason, P. K. Coyle, C. C. Ford, A. Noronha, and K. W. Rammohan Issues and Practices in Multiple Sclerosis Neurorehabil Neural Repair, December 1, 2002; 16(4): 307 - 320. [Abstract] [PDF] |
||||
![]() |
M. Clanet, E.W. Radue, L. Kappos, H.P. Hartung, R. Hohlfeld, M. Sandberg-Wollheim, M.F. Kooijmans-Coutinho, E.C. Tsao, and A.W. Sandrock A randomized, double-blind, dose-comparison study of weekly interferon {beta}-1a in relapsing MS Neurology, November 26, 2002; 59(10): 1507 - 1517. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Fisher, R. A. Rudick, J. H. Simon, G. Cutter, M. Baier, J. -C. Lee, D. Miller, B. Weinstock-Guttman, M. K. Mass, D. S. Dougherty, et al. Eight-year follow-up study of brain atrophy in patients with MS Neurology, November 12, 2002; 59(9): 1412 - 1420. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Galetta, C. Markowitz, and A. G. Lee Immunomodulatory Agents for the Treatment of Relapsing Multiple Sclerosis: A Systematic Review Arch Intern Med, October 28, 2002; 162(19): 2161 - 2169. [Abstract] [Full Text] [PDF] |
||||
![]() |
E L. Hoogervorst, C H Polman, and F Barkhof Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone Multiple Sclerosis, October 1, 2002; 8(5): 415 - 419. [Abstract] [PDF] |
||||
![]() |
R Leigh, J Ostuni, D Pham, A Goldszal, B K Lewis, T Howard, N Richert, H McFarland, and J A Frank Estimating cerebral atrophy in multiple sclerosis patients from various MR pulse sequences Multiple Sclerosis, October 1, 2002; 8(5): 420 - 429. [Abstract] [PDF] |
||||
![]() |
N. De Stefano, S. Narayanan, S. J. Francis, S. Smith, M. Mortilla, M. C. Tartaglia, M. L. Bartolozzi, L. Guidi, A. Federico, and D. L. Arnold Diffuse Axonal and Tissue Injury in Patients With Multiple Sclerosis With Low Cerebral Lesion Load and No Disability Arch Neurol, October 1, 2002; 59(10): 1565 - 1571. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. F. Kalkers, N. Ameziane, J. C. J. Bot, A. Minneboo, C. H. Polman, and F. Barkhof Longitudinal Brain Volume Measurement in Multiple Sclerosis: Rate of Brain Atrophy Is Independent of the Disease Subtype Arch Neurol, October 1, 2002; 59(10): 1572 - 1576. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Gonen, D. M. Moriarty, B. S. Y. Li, J. S. Babb, J. He, J. Listerud, D. Jacobs, C. E. Markowitz, and R. I. Grossman Relapsing-remitting Multiple Sclerosis and Whole-Brain N-Acetylaspartate Measurement: Evidence for Different Clinical Cohorts—Initial Observations Radiology, October 1, 2002; 225(1): 261 - 268. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Rao, N. Richert, T. Howard, B.K. Lewis, C.N. Bash, H.F. McFarland, and J. A. Frank Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFN{beta}-1b Neurology, September 10, 2002; 59(5): 688 - 694. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. McFarland, F. Barkhof, J. Antel, and D. Miller The role of MRI as a surrogate outcome measure in multiple sclerosis Multiple Sclerosis, September 1, 2002; 8(1_suppl): 40 - 51. [Abstract] [PDF] |
||||
![]() |
R. J. Fox, E. Fisher, R. Rudick, B.O. Khatri, M.P. McQuillen, and D. S. Goodin Disease modifying therapies in multiple sclerosis Neurology, August 13, 2002; 59(3): 471 - 473. [Full Text] [PDF] |
||||
![]() |
C M Dalton, P A Brex, R Jenkins, N C Fox, K A Miszkiel, W R Crum, J I O'Riordan, G T Plant, A J Thompson, and D H Miller Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis J. Neurol. Neurosurg. Psychiatry, August 1, 2002; 73(2): 141 - 147. [Abstract] [Full Text] [PDF] |
||||
![]() |
S J Hickman, C M. Brierley, P A Brex, D G MacManus, N J Scolding, D A. Compston, and D H Miller Continuing optic nerve atrophy following optic neuritis: a serial MRI study Multiple Sclerosis, August 1, 2002; 8(4): 339 - 342. [Abstract] [PDF] |
||||
![]() |
D. H. Miller, F. Barkhof, J. A. Frank, G. J. M. Parker, and A. J. Thompson Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance Brain, August 1, 2002; 125(8): 1676 - 1695. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Filippi and R. I. Grossman MRI techniques to monitor MS evolution: The present and the future Neurology, April 23, 2002; 58(8): 1147 - 1153. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Calabresi Considerations in the treatment of relapsing-remitting multiple sclerosis Neurology, April 23, 2002; 58(90084): S10 - 22. [Abstract] [Full Text] |
||||
![]() |
D. L. Arnold and P.M. Matthews MRI in the diagnosis and management of multiple sclerosis Neurology, April 23, 2002; 58(90084): S23 - 31. [Abstract] [Full Text] |
||||
![]() |
C Gasperini, A Paolillo, E Giugni, S Galgani, F Bagnato, C Mainero, E Onesti, S Bastianello, and C Pozzilli MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a Multiple Sclerosis, April 1, 2002; 8(2): 119 - 123. [Abstract] [PDF] |
||||
![]() |
F. Bonneville, D. M. Moriarty, B. S.Y. Li, J. S. Babb, R. I. Grossman, and O. Gonen Whole-Brain N-Acetylaspartate Concentration: Correlation with T2-Weighted Lesion Volume and Expanded Disability Status Scale Score in Cases of Relapsing-Remitting Multiple Sclerosis AJNR Am. J. Neuroradiol., March 1, 2002; 23(3): 371 - 375. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Giess, M. Maurer, R. Linker, R. Gold, M. Warmuth-Metz, K. V. Toyka, M. Sendtner, and P. Rieckmann Association of a Null Mutation in the CNTF Gene With Early Onset of Multiple Sclerosis Arch Neurol, March 1, 2002; 59(3): 407 - 409. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |